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A B S T R A C T
Objectives: High-level aminoglycoside, ampicillin and vancomycin resistance and virulence genes among
enterococcal isolates collected from healthy middle-school children in Ardabil, Iran, during 2016 were
investigated.
Methods: Totally, 305 faecal specimens were collected. Isolates underwent antimicrobial susceptibility
testing, virulence gene detection and molecular typing.
Results: Totally, 409 enterococcal isolates were collected, comprising Enterococcus faecium (235; 57.5%),
Enterococcus faecalis (56; 13.7%) and other Enterococcus spp. (118; 28.9%). Overall, 71 (17.4%),11 (2.7%) and
10 (2.4%) isolates were identified as high-level streptomycin-resistant (HLSR), high-level gentamicin-
resistant (HLGR) and ampicillin-resistant (AR), respectively. Among HLSR isolates, 40 (56.3%), 5 (7.0%) and
26 (36.6%) were E. faecium, E. faecalis and other Enterococcus spp., respectively. Among HLGR isolates
4 (36.4%) and 7 (63.6%) and among AR isolates 7 (70.0%) and 3 (30.0%) were E. faecium and other
Enterococcus spp., respectively. Accordingly, 21.6%, 3.6% and 3.3% of subjects were colonised with HLSR,
HLGR and AR Enterococcus spp. Carriage of HLGR, HLSR and AR isolates was associated with prior
antibiotic consumption (P  0.05). Additionally, male sex and antacid consumption were associated with
AR enterococcal carriage. Moreover, 69 (97.2%), 10 (90.9%) and 9 (90.0%) of HLSR, HLGR and AR isolates
were multidrug-resistant, respectively. No vancomycin-resistant enterococci were detected. ERIC-PCR
revealed high genetic diversity among isolates. gelE and asa1 were major virulence genes both in
E. faecalis and E. faecium. Presence of gelE was associated with HLSR and HLGR phenotypes (P  0.05).
Conclusion: Community intestinal carriage of HLSR enterococci was high; however, carriage of HLGR and
AR enterococci was low.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The genus Enterococcus includes several species. Enterococcus
faecalis and Enterococcus faecium are major human pathogens [1]
causing a variety of infections, including urinary tract infection,
bacteraemia, endocarditis and meningitis [2]. The pathogenesis
of enterococcal infections is predominately attributed to their
intrinsic resistance to certain classes of antibiotics and their
remarkable ability to develop resistance to most commonly
used antimicrobial agents [3]. There are several virulence
factors in E. faecalis and E. faecium involved in the pathogenesis
of enterococcal infections, including aggregation substances,
gelatinase, hyaluronidase, and surface proteins such as collagen* Corresponding author.
E-mail address: m.arzanlou@arums.ac.ir (M. Arzanlou).
https://doi.org/10.1016/j.jgar.2019.06.022
2213-7165/© 2019 International Society for Antimicrobial Chemotherapy. Published by
creativecommons.org/licenses/by-nc-nd/4.0/).adhesin, the adhesin-like E. faecalis and E. faecium antigen A, and
enterococcal surface protein [4].
Treatment of severe invasive enterococcal infections typically
includes the combination of a cell-wall-active agent (e.g. ampicillin
and vancomycin) and an aminoglycoside (gentamicin or strepto-
mycin). Resistance to these antibiotics weakens the synergistic
activity of combination therapy [5]. Resistance to high levels of
aminoglycoside antibiotics commonly occurs due to the produc-
tion of aminoglycoside-modifying enzymes. These enzymes are
encoded within mobile genetic elements and are widespread
among Enterococcus spp., conferring high-level aminoglycoside
resistance (HLAR) [6].
Bacteria colonising the gastrointestinal tract are critically
important in many opportunistic infections affecting immuno-
compromised individuals [7]. Enterococci are common intestinal
microflora in humans and animals and are also present in Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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[1]. People colonised with resistant enterococcal strains are not
only at risk of being infected but are also a potential source for the
dissemination of micro-organisms to the environment and to other
people [7]. It is well known that intestinal colonisation with
resistant enterococcal strains is common in hospitalised patients
[8]. However, the rate of colonisation in the community setting is
not well established.
This study was performed to determine the prevalence of
intestinal carriage of high-level streptomycin-resistant (HLSR),
high-level gentamicin-resistant (HLGR), vancomycin-resistant and
ampicillin-resistant (AR) Enterococcus spp. in a community setting
in Iran as well as the distribution of their virulence determinants,
genetic relatedness between isolates and factors associated with
antimicrobial resistance characteristics.
2. Materials and methods
2.1. Subjects and sampling
Subjects were randomly selected students (age 12–14 years)
recruited from 19 male/female middle schools in Ardabil city,
northwestern Iran. Between May and June 2016, 305 faecal
samples were collected. The study was based on informed parental
consent of each student and was approved by the regional Ethics
Committee of Ardabil University of Medical Sciences (Ardabil,
Iran). A questionnaire was completed for each student to record
variables including age, sex, stature, weight, number of family
members, hospital admission in past 12 months, hospitalisation
of a family member in past 12 months, antibiotic consumption in
past 3 months, alcohol consumption in past 3 months, antacid
consumption in past 3 months, having diarrhoea or constipation in
past 3 months, autoimmune diseases, smoking, type of nutritionTable 1
Deoxyoligonucleotide primers used in this study.
Gene Oligonucleotide sequence (5'→3') 
16S rRNA GGA TTA GAT ACC CTG GTA GTC C









aac(6')-Ie–aph(2")-Ia GAG CAA TAA GGG CAT ACC AAA
GTT CCT ATT TCT TCT TCA CTA TCT TC
aph(2")-Ib TCA AAT CCC TGC GGT AGT GTA
CGC CAA AAT CAA TAA CTC CAA
aph(2")-Ic GAG GGC TTT AGG AAT TAC GC
ACA CAA CCG ACC AAC AGA GG
aph(2")-Id TAA TCT GCC GAA GCA ATC TCA
TAA TCC CTC TTC ATA CCA ATC C
ant(3")-Ia ACC GTA AGG CTT GAT GAA ACA
GCC GAC TAC CTT GGT GAT CTC
aph(3')-IIIa GGCTAAAATGAGAATATCACCGG
CTTTAAAAAATCATACAGCTCGCG
ant(60)-Ia GCC CTT GGA AGA GTT AGA TAA TT










GACTGACGTCCAAGTTTCCAA(all/vegetarian/meat-eater), milk consumption (once/twice or
thrice per week), kinds of dairy consumed (pasteurised/non-
pasteurised), red meat consumption (regularly/rarely), chicken
consumption (regularly/rarely) and hand-washing practices (soap/
water/none).
2.2. Isolation and identification of bacteria
Approximately 0.5 g of faecal sample was cultured in 5 mL of
brain–heart infusion (BHI) broth (BioMaxima S.A., Lublin, Poland)
containing 7.5% NaCl (Merck, Darmstadt, Germany) for 24 h at
35 C. Then, a 50 mL aliquot of bacterial culture was seeded onto m-
Enterococcus agar (QUELAB, Montreal, Canada) plates and was
further incubated at 37 C for 24 h. Suspected Enterococcus spp.
colonies were subjected to catalase test as well as hydrolysis of
esculin (Merck) and L-pyrrolidonyl arylamidase (PYR) (HiMedia,
Mumbai, India). Definitive identification of isolates as Enterococcus
spp. was done by targeting the 16S rRNA gene based on a PCR assay
as described previously [9]. Genomic DNA was extracted from
overnight cultures using a DNA extraction kit (DNPTM; Sinaclon,
Tehran, Iran). Amplification was performed in a DNA Thermal
Cycler (Bio-Rad, Hercules, CA, USA) with an initial denaturation
step at 95 C for 5 min, then 25 cycles of denaturing at 94 C for
1 min, annealing at 56 C for 1 min with specific primers (Table 1)
and polymerisation at 72 C for 1 min, followed by a single final
extension step at 72 C for 7 min. Species identification of E. faecium
and E. faecalis was further performed by PCR with primers (Table 1)
targeted to the ddl genes as described elsewhere [10] with slight
modifications as described below. The PCR conditions consisted of
a pre-denaturation step at 95 C for 5 min, followed by 30 cycles of
1 min at 95 C, 45 s at 45 C for ddl of E. faecalis and 47 C for ddl of E.
faecium and 45 s at 72 C. A final extension step was performed at
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DNA Stain (Sinaclon) and the DNA bands were visualised by
ultraviolet illumination (Uvitec Ltd., Cambridge, UK). Enterococcus
faecalis ATCC 29212 and E. faecium ATCC 19434 were used as
positive controls, and nuclease-free distilled water was used as a
negative control. In addition, representative genes were randomly
selected and sequenced to confirm their identity.
Isolates were stored in BHI broth with 15% glycerol (Merck) at
80 C until further analysis.
2.3. Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by the disk
diffusion method on Mueller–Hinton agar (BioMaxima) according to
Clinical and Laboratory Standards Institute (CLSI) guidelines [11].
The tested antibiotics (Padtan Teb, Tehran, Iran) were cipro-
floxacin (5 mg), erythromycin (15 mg), nitrofurantoin (300 mg),
tetracycline (30 mg), rifampicin (5 mg), chloramphenicol (30 mg),
penicillin G (10 mg) and teicoplanin (30 mg). Enterococcus faecalis
ATCC 29212 was used as a reference strain for antimicrobial
susceptibility testing.
HLAR was determined by the agar-screen method. Briefly, 10 mL
of a 0.5 McFarland bacterial suspension was spotted onto a BHI agar
(SRL Diagnostics, Mumbai, India) surface containing 500 mg/mL
gentamicin and 2000 mg/mL streptomycin separately. Plates were
incubated at 35  2 C for 24–48 h and were inspected for growth
(if susceptible at 24 h, plates were re-incubated for an additional
24 h). Growth of >1 colony in a spotted area was considered as
HLAR.
The minimum inhibitory concentration (MIC) of ampicillin
((Bio Basic, Ontario, Canada)) was determined by the standard
agar dilution method (concentration range, 0.12–512 mg/mL).
Resistance to ampicillin was defined as an MIC  16 mg/mL [11].
BHI agar containing 6 mg/mL vancomycin ((Bio Basic, Ontario,
Canada)) was used for detection of vancomycin-resistant isolates.
The MICs of isolates growing on BHI–vancomycin screening agar
were determined by the agar dilution method (concentration
range, 0.12–512 mg/mL). Resistance to vancomycin was defined as
an MIC  32 mg/mL [11].
All susceptibility tests were performed and interpreted
according to the guidelines of the CLSI. Enterococcus faecalis ATCC
29212 was used as a negative control strain.
2.4. PCR amplification of high-level aminoglycoside resistance genes
The presence of the high-level gentamicin resistance-encoding
genes aac(6')-Ie–aph(2")-Ia, aph(2")-Ib, aph(2")-Ic and aph(2")-Id
and the high-level streptomycin resistance-encoding genes ant
(3")-Ia and ant(60)-Ia were investigated by multiplex PCR using
specific primers listed in Table 1. Multiplex PCR was performed in
30 cycles of denaturation at 94 C for 1 min, annealing at 56 C
for 1 min and extension at 72 C for 1 min, followed by one cycle at
72 C for 10 min [12]. The aph(3")-IIIa gene amplification was
performed as described above with a distinct annealing tempera-
ture of 58 C [13]. PCR products were analysed as described earlier
in this text. Representative genes were randomly selected and
were sequenced to confirm their identity. Genes encoding
vancomycin resistance (vanA and vanB) were identified according
to previous reports [10].
Genes encoding five common enterococcal virulence determi-
nants, including aggregation substance (asa1), cytolysin (cylA),
enterococcal surface protein (esp), gelatinase (gelE) and hyaluroni-
dase (hyl), were detected using specific primers (Table 1) in a
multiplex PCR reaction as described previously [14]. Briefly, PCR
was performed with an initial denaturation at 94 C for 4 min, then
30 cycles of denaturation at 94 C for 1 min, annealing at 56 C for1 min and extension at 72 C for 1 min, and a final extension at 72 C
for 10 min. PCR products were size-fractionated by agarose gel
electrophoresis and were visualised as described above. A
representative PCR product for each virulence gene was randomly
selected and sequenced to confirm its identity.
2.5. Enterobacterial repetitive intergenic consensus (ERIC)-PCR
ERIC-PCR was performed for genotyping of the isolates as
described previously [15]. Reactions were performed in a total
volume of 25 mL containing 12.5 mL of PCR Master Mix, 1 mL of
template DNA, 2.5 mL of ERIC1-R primer (5ʹ-ATGTAAGCTCCTGGG-
GATTCAC-3ʹ) and 9 mL of distilled deionised water. Amplifications
were performed with a cycling programme consisting of an initial
denaturation step at 94 C for 3 min, then 35 cycles of 94 C for 30 s,
48 C for 60 s and 72 C for 5 min, and a final extension step at 72 C
for 7 min. Amplicons were size-fractionated by agarose gel
electrophoresis at 80 V for 2 h through 1.5% agarose gels, were
stained with Safe DNA Stain and were visualised and photographed
as described earlier. ERIC patterns were analysed using BioNu-
merics II software 7.0 trial version (Applied Maths, Kortrijk,
Belgium), and similarities among ERIC-PCR profiles were deter-
mined using the Dice coefficient and unweighted pair-group
method with arithmetic mean (UPGMA). Isolates with an 80% level
of similarity were grouped in the same cluster and were considered
as clonally related.
2.6. Statistical analyses
SPSS software v.11.5 (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Association of risk factors with antimicrobial
resistance was calculated using the χ2 test. A P-value of  0.05 was
considered statistically significant.
3. Results
3.1. Identification of bacterial isolates
A total of 409 enterococcal isolates were collected from 305
faecal samples obtained from healthy children [176 (57.7%) males
and 129 (42.3%) females]. Genotypic identification of 409
enterococcal isolates showed that 235 (57.5%) were E. faecium,
56 (13.7%) were E. faecalis and 118 (28.9%) were other Enterococcus
spp. Faecal samples from four children did not have any
enterococcal colonies on m-Enterococcus agar. The 301 remaining
children were all colonised by one to two different enterococcal
types. In total, 215 (70.5%), 56 (18.4%) and 103 (33.8%) of the 305
subjects were colonised by E. faecium, E. faecalis and other
Enterococcus spp., respectively. Among them, 135 (44.3%), 16
(5.2%) and 41 (13.4%) were colonised with only E. faecium, E. faecalis
or other Enterococcus spp., respectively; 27 (8.9%), 33 (10.8%) and
13 (4.3%) were colonised by a combination of E. faecium + E. faecalis,
E. faecium + other Enterococcus spp. and E. faecalis + other
Enterococcus spp., respectively; and 20 (6.6%) and 16 (5.2%) were
colonised by a combination of E. faecium + E. faecium and other
Enterococcus spp. + other Enterococcus spp., respectively.
3.2. Antimicrobial susceptibility testing
The susceptibility patterns of the isolates are presented in
Table 2. Overall, teicoplanin (0% resistant) and rifampicin (83.4%
resistant) were the most and least active antibiotics, respectively,
against the enterococcal isolates. The rates of antibiotic non-
susceptibility (intermediate and resistant) for all antibiotics tested
(except for chloramphenicol, rifampicin and tetracycline) were
higher in E. faecium isolates compared with E. faecalis isolates.
Table 2




E. faecalis (n = 56) [n (%)] E. faecium (N = 235) [n (%)] Other Enterococcus spp. (N = 118) [n (%)] Total (N = 409) [n (%)]
R I S R I S R I S R I S
Ciprofloxacin 1 (1.8) 20 (35.7) 35 (62.5) 48 (20.4) 86 (36.6) 101 (43.0) 16 (13.6) 34 (28.8) 68 (57.6) 65 (15.9) 140 (34.2) 204 (49.9)
Chloramphenicol 6 (10.7) 5 (8.9) 45 (80.4) 13 (5.5) 11 (4.7) 211 (89.8) 8 (6.8) 16 (13.6) 94 (79.7) 27 (6.6) 32 (7.8) 350 (85.6)
Erythromycin 19 (33.9) 29 (51.8) 8 (14.3) 96 (40.9) 122 (51.9) 17 (7.2) 54 (45.8) 57 (48.3) 7 (5.9) 169 (41.3) 208 (50.9) 32 (7.8)
Nitrofurantoin 3 (5.4) 8 (14.3) 45 (80.4) 61 (26.0) 46 (19.6) 128 (54.5) 15 (12.7) 14 (11.9) 89 (75.4) 79 (19.3) 68 (16.6) 262 (64.1)
Penicillin G 15 (26.8) – 41 (73.2) 112 (47.7) – 123 (52.3) 42 (35.6) – 76 (64.4) 169 (41.3) – 240 (58.7)
Ampicillina – – 56 (100) 7 (3.0) – 228 (97.0) 3 (2.5) – 115 (97.5) 10 (2.4) – 399 (97.6)
Rifampicin 47 (83.9) 5 (8.9) 4 (7.1) 203 (86.4) 6 (2.6) 26 (11.1) 91 (77.1) 11 (9.3) 16 (13.6) 341 (83.4) 22 (5.4) 46 (11.2)
Tetracycline 45 (80.4) 2 (3.6) 9 (16.1) 146 (62.1) 14 (6.0) 75 (31.9) 82 (69.5) 6 (5.1) 30 (25.4) 273 (66.7) 22 (5.4) 114 (27.9)
Teicoplanin – 1 (1.8) 55 (98.2) – – 235 (100) – – 118 (100) – 1 (0.2) 408 (99.8)
R, resistant; I, intermediate-resistant; S, susceptible.
a Susceptibility profile was determined by the agar dilution method.
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faecalis and E. faecium isolates, respectively. Vancomycin, teico-
planin and ampicillin showed the greatest activity against both
species.
Using BHI–vancomycin screening agar (6 mg/mL), 23 (5.6%) of
the 409 enterococcal isolates, including 14 (60.9%) E. faecium, 1
(4.3%) E. faecalis and 8 (34.8%) other Enterococcus spp. showed
growth. However, in MIC testing 2/235 (0.9%) of the E. faecium
isolates were confirmed as vancomycin-intermediate (MIC = 8 mg/
mL). No vanA or vanB genes were found in isolates with
intermediate vancomycin resistance.
The MIC50 (MIC required to inhibit 50% of isolates) of ampicillin
was 1 mg/mL for all species. Of the 409 isolates, 10 (2.4%) were
found to be resistant to ampicillin (MIC  16 mg/mL), including 7
(70.0%) E. faecium and 3 (30.0%) other Enterococcus spp. The MICs of
ampicillin ranged between 16 mg/mL and 128 mg/mL in AR isolates
(Table 3). In total, 10 (3.3%) of the 305 subjects were colonised with
AR enterococci, including 7 (2.3%) and 3 (1.0%) with AR E. faecium
and other AR Enterococcus spp., respectively. Ampicillin resistance
was positively associated with sex as well as antibiotic and antacid
consumption (P  0.05) (Table 4). Of the 10 AR isolates, 9 (90.0%)
were multidrug-resistant (MDR) (resistant to at least three
antibiotic classes) (Table 5).
High-level gentamicin and streptomycin resistance were
detected in 11 (2.7%) and 71 (17.4%) of the 409 isolates, respectively.
Among the 71 HLSR isolates, 40 (56.3%), 5 (7.0%) and 26 (36.6%)
were E. faecium, E. faecalis and other Enterococcus spp., respectively.
Among the 11 HLGR isolates, 4 (36.4%) and 7 (63.6%) were E.
faecium and other Enterococcus spp., respectively (Table 6).
The HLGR isolates included 4 (1.7%) of 235 E. faecium and 7
(5.9%) of 118 other Enterococcus spp. isolates. The HLSR isolates
included 5 (8.9%) of 56 E. faecalis, 40 (16.9%) of 235 E. faecium and
26 (22.0%) of 118 other Enterococcus spp. In addition, combined
resistance profiles of HLSR + AR and HLSR + HLGR + AR were each
observed in 1 (0.4%) of 235 E. faecium isolates. Eight (2.0%) isolates
showed a combined HLSR + HLGR profile, including 1/235 (0.47%)
E. faecium and 7/118 (5.9%) other Enterococcus spp. Accordingly,
overall 21.6%, 3.6% and 3.3% of subjects were found to be colonised
with HLSR, HLGR and AR enterococci. HLSR, HLGR and AR E.Table 3
Distribution of ampicillin minimum inhibitory concentrations (MICs) determined by the 
Species No. (%) at MIC (mg/mL) of: 
<0.12 0.25 0.5 1 2 
Total Enterococcus spp. (N = 409) 6 (1.5) 4 (1) 67 (16.4) 247 (60.4) 56 
E. faecium (N = 235) 6 (2.6) 1 (0.4) 27 (11.5) 146 (62.1) 34 
E. faecalis (N = 56) - 1 (1.8) 15 (26.8) 35 (62.5) 4 (
Other Enterococcus spp. (N = 118) - 2 (1.7) 25 (21.2) 66 (55.9) 18 
MIC50/90, MIC required to inhibit 50% and 90% of the isolates, respectively.faecium and other Enterococcus spp. carriage was detected in 13.8%,
1.3% and 2.3% and in 8.2%, 2.3% and 1.0% of subjects, respectively.
Moreover, 1.3% of subjects were colonised with HLGR E. faecalis
isolates and 0.32% of subjects were colonised with E. faecium
isolates showing a combined resistance profile of HLSR + AR and
HLSR + HLGR + AR. Eight subjects were colonised with organisms
showing a combined profile of HLGR + HLSR, including 0.32% and
6.0% with E. faecium and other Enterococcus spp., respectively.
The aminoglycoside-modifying enzyme-encoding genes aac
(6')-Ie–aph(2")-Ia and aph(3')-IIIa were found in 8 (72.7%) and 6
(54.5%) of the 11 HLGR isolates. The ant(6')-Ia gene encoding
streptomycin resistance was detected in 35 (49.3%) of the 71 HLSR
isolates.
Antibiotic consumption was found to be a risk factor for carriage
both of HLGR and HLSR Enterococcus spp. (P  0.05). Number of
students in class was associated with carriage of HLSR Enterococcus
spp. (P  0.05) (Table 4). In this study, 69 (97.2%) and 10 (90.9%) of
the HLSR and HLGR isolates were MDR (resistant to at least three
antibiotic classes), respectively (Table 5).
3.3. Detection of virulence genes
Among the 56 E. faecalis isolates, 34 (60.7%) were positive for
gelE, 30 (53.6%) for asa1, 18 (32.1%) for esp, 7 (12.5%) for cylA and 3
(5.4%) for hyl. Among the 235 E. faecium isolates, 107 (45.5%) were
positive for gelE, 73 (31.1%) for asa1, 32 (13.6%) for esp, 13 (5.5%) for
hyl and 7 (3.0%) for cylA (Table 7). Virulence gene profile analyses
showed that of the 56 E. faecalis isolates, 50 (89.3%) contained at
least one virulence factor gene. Collectively, 1 (1.8%) isolate
contained four genes and 10 (17.9%), 19 (33.9%) and 20 (35.7%)
isolates harboured three, two and one genes, respectively. Of the
235 E. faecium isolates, 139 (59.1%) possessed at least one virulence
determinant gene. Collectively, 1 (0.4%) isolate contained five
genes and 2 (0.9%), 16 (6.8%), 51 (21.7%) and 69 (29.4%) isolates
contained four, three, two and one genes, respectively (Table 7).
Statistical analyses showed a positive correlation between HLAR
phenotype and the presence of the gelatinase encoding gene gelE
(P  0.05) (Table 8).agar dilution method of enterococcal isolates collected from healthy children in Iran.
MIC (mg/mL)
4 8 16 32 64 128 MIC50 MIC90
(13.7) 16 (3.9) 3 (0.7) 7 (1.7) 1 (0.2) – 2 (0.5) 1 2
(14.5) 12 (5.1) 2 (0.9) 5 (2.1) 1 (0.4) – 1 (0.4) 1 2
7.1) 1 (1.8) – – – – – 1 1
(15.3) 3 (2.5) 1 (0.8) 2 (1.7) – – 1 (0.8) 1 2
Table 4
Factors associated with HLSR, HLGR and AR enterococcal carriage in healthy children in Iran.
Risk factor Subjects [n (%)]
HLSR (N = 66) Non-HLSR controls
(N =239)
P-value HLGR (N =11) Non-HLGR controls
(N = 294)
P-value AR (N =10) Non-AR controls
(N=295)
P-value
Sex M/F [n (%)] 43 (62.5)/23 (34.8) 133 (55.6)/106 (44.4) 0.16 8 (72.7)/3 (27.3) 168 (57.1)/126 (42.9) 0.30 10 (100)/0 166 (56.3)/129 (43.7) 0.006*
Mean stature (cm) 155.213.38 157.88.55 0.09 163.2714.82 157.09.5 0.04* 161.47.64 157.19.9 0.18
Mean weight (kg) 50.2711.42 50.6711.3 0.80 59.559.43 50.2411.25 0.07 53.7015.7 50.4711.5 0.37
Mean no. of family members 4.450.96 4.311.5 0.46 4.731.19 4.331.4 0.36 4.201.03 4.31.4 0.75
Mean no. of students in class 32.153.75 30.313.9 0.001* 31.364.17 30.683.94 0.57 31.705.25 30.673.9 0.41
Hospital admissiona 5 (7.6) 12 (5.0) 0.42 2 (18.2) 15 (5.1) 0.06 0 17 (5.8) 0.43
Hospitalisation of a family membera 12 (18.2) 42 (17.6) 0.90 2 (18.2) 52 (17.7) 0.96 3 (30.0) 51 (17.3) 0.30
Antibiotic consumptionb 20 (30.3) 46 (19.2) 0.05* 5 (45.5) 61 (20.7) 0.05* 7 (70.0) 59 (20.0) 0.000*
Antacid consumptionb 5 (7.6) 11 (4.6) 0.5 1 (9.1) 15 (5.1) 0.55 2 (20.0) 14 (4.7) 0.02*
Having diarrhoea or constipationb 11 (16.7) 28 (11.7) 0.26 1 (9.1) 38 (12.9) 0.70 2 (20.0) 37 (12.5) 0.48
Autoimmune disease 2 (3.0) 5 (2.1) 0.79 0 7 (2.4) 0.60 0 295 (100) 0.60
Smoking 0 239 (100) 0 0 294 (100) 0.07 0 295 (100) 0
Alcohol consumptionb 1 (1.5) 6 (2.5) 0.63 0 7 (2.4) 0.36 0 295 (100) 0.6
Type of nutrition (all/vegetarian/meat-eater) 61 (92.4)/1 (1.5)/4 (6.1) 225 (94.1)/4 (1.7)/10 (4.2) 0.81 10 (90.9)/0/1 (9.1) 276 (93.9)/5 (1.7)/13 (4.4) 0.7 10 (100)/0/0 276 (93.6)/5 (1.7)/14 (4.7) 0.7
Milk consumption (once/twice or thrice per
week)
38 (57.6)/28 (42.4) 133 (55.6)/106 (44.4) 0.78 8 (72.7)/3 (27.3) 163 (55.4)/131 (44.6) 0.25 6 (60.0)/4 (40.0) 165 (55.9)/130 (44.1) 0.79
Kinds of dairy consumed (pasteurised/non-
pasteurised)
37 (56.1)/29 (43.9) 160 (66.9)/79 (33.1) 0.10 8 (72.7)/3 (27.3) 189 (64.3)/105 (35.7) 0.50 7 (70.0)/3 (30.0) 190 (64.4)/105 (35.6) 0.71
Red meat consumption (regularly/rarely) 36 (54.5)/30 (45.5) 112 (46.9)/127 (53.1) 0.26 6 (54.5)/5 (45.5) 142 (48.3)/152 (51.7) 0.68 7 (70.0)/3 (30.0) 141 (47.8)/154 (52.2) 0.27
Chicken consumption (regularly/rarely) 40 (60.6)/26 (39.4) 161 (67.4)/78 (32.6) 0.30 7 (63.6)/4 (36.4) 194 (66.0)/100 (34.0) 0.87 7 (70.0)/3 (30.0) 194 (65.8)/101 (34.2) 0.78
Washing hands (soap/water/none) 58 (87.9)/7 (10.6)/1 (1.5) 195 (81.6)/41 (17.2)/3 (1.3) 0.43 243 (82.7)/47 (16.0)/4 (1.4) 0.75 10 (100)/0/0 243 (82.4)/48 (16.3)/4 (1.4) 0.34
HLSR, high-level streptomycin-resistant; HLGR, high-level gentamicin-resistant; AR, ampicillin-resistant.
a In past 12 months.
b In past 3 months.






















Antimicrobial non-susceptibility (intermediate-resistant + resistant) profile of HLSR, HLGR and AR Enterococcus spp. isolated from healthy children in Iran
Enterococcus spp. Phenotypic resistance profile No. (%) of isolates No. of antibiotic classes Total [n (%)]a
HLSR (N = 71) PEN, CIP, ERY, TET, NIT, CHL, RIF 1 (1.4) 7 1 (1.4)
PEN, CIP, ERY, TET, NIT, RIF 10 (14.1) 6 15 (21.1)
PEN, CIP, ERY, TET, CHL, RIF 5 (7.0) 6
CIP, ERY, TET, NIT, RIF 6 (8.5) 5 25 (35.2)
PEN, CIP, ERY, NIT, RIF 1 (1.4) 5
PEN, CIP, ERY, TET, NIT 1 (1.4) 5
CIP, ERY, TET, NIT, CHL 1 (1.4) 5
CIP, ERY, TET, CHL, RIF 1 (1.4) 5
PEN, ERY, TET, NIT, RIF 3 (4.2) 5
PEN, CIP, ERY, TET, RIF 6 (8.5) 5
PEN, CIP, ERY, TET, RIF 6 (8.5) 5
CIP, ERY, NIT, RIF 2 (2.8) 4 13 (18.3)
CIP, ERY, TET, RIF 6 (8.5) 4
ERY, TET, NIT, RIF 1 (1.4) 4
PEN, CIP, ERY, RIF 1 (1.4) 4
PEN, ERY, NIT, RIF 1 (1.4) 4
ERY, TET, CHL, RIF 2 (2.8) 4
CIP, TET, NIT 1 (1.4) 3 15 (21.1)
TET, NIT, RIF 1 (1.4) 3
ERY, NIT, RIF 1 (1.4) 3
ERY, TET, RIF 8 (11.3) 3
CIP, ERY, RIF 2 (2.8) 3
PEN, ERY, RIF 1 (1.4) 3
PEN, ERY, TET 1 (1.4) 3
ERY, RIF 1 (1.4) 2 1 (1.4)
PEN 1 (1.4) 1 1 (1.4)
AR (N = 10) PEN, CIP, ERY, TET, NIT, CHL, RIF 2 (20.0) 7 2 (20.0)
PEN, CIP, ERY, TET, NIT, RIF 4 (40.0) 6 4 (40.0)
PEN, CIP, ERY, TET, RIF 1 (10.0) 5 1 (10.0)
CIP, ERY, NIT 1 (10.0) 3 2 (20.0)
PEN, ERY, TET 1 (10.0) 3
CIP 1 (10.0) 1 1 (10.0)
HLGR (N = 11) PEN, CIP, ERY, TET, NIT, RIF 2 (18.2) 6 3 (27.3)
PEN, CIP, ERY, TET, CHL, RIF 1 (9.1) 6
CIP, ERY, TET, NIT, RIF 2 (18.2) 5 2 (18.2
CIP, ERY, TET, RIF 1 (9.1) 4 2 (18.2)
PEN, CIP, ERY, RIF 1 (9.1) 4
ERY, TET, RIF 3 (27.3) 3 3 (27.3)
ERY 1 (9.1) 1 1 (9.1)
HLSR, high-level streptomycin-resistant; HLGR, high-level gentamicin-resistant; AR, ampicillin-resistant; PEN, penicillin G; CIP, ciprofloxacin; ERY, erythromycin; TET,
tetracycline; NIT, nitrofurantoin; CHL, chloramphenicol; RIF, rifampicin.
a Total number of isolates resistant to same number of antibiotic classes.
Table 6
Distribution of HLSR, HLGR, AR and VIR phenotypes among Enterococcus spp. isolated from healthy children in Iran.
Resistance phenotype No. (%) of isolates
E. faecium E. faecalis Other Enterococcus spp. Total (N = 409)
HLSR 42 (59.2) 4 (5.6) 25 (35.2) 71 (17.4)
HLGR 4 (36.4) – 7 (63.6) 11 (2.7)
AR 7 (70.0) – 3 (30.0) 10 (2.4)
VIR 2 (100) – – 2 (0.5)
HLSR + AR 1 (100) – – 1 (0.2)
HLSR + HLGR + AR 1 (100) – – 1 (0.2)
HLSR + HLGR 1 (12.5) – 7 (87.5) 8 (2.0)
HLSR, high-level streptomycin-resistant; HLGR, high-level gentamicin-resistant; AR, ampicillin-resistant; VIR, vancomycin-intermediate-resistant.
140 E. Jannati et al. / Journal of Global Antimicrobial Resistance 20 (2020) 135–1443.4. ERIC-PCR analysis
The ERIC-1R primer in E. faecium generated 4–13 amplicons
with molecular weights ranging from 100 to 16 000 bp. According
to the dendrogram with 80% similarity, 25 different genotypes
(subgroups) were observed (Fig. 1). Of the 47 isolates tested, 12
isolates provided unique genotypes, whereas genotype subgroup 5
contained the highest number of isolates (n = 5).
The ERIC-1R primer in E. faecalis generated 4–11 amplicons with
molecular weights ranging from 120 to 18 000 bp. According to
the dendrogram with 80% similarity, 10 different genotypes(subgroups) were observed (Fig. 2). Of the 19 isolates tested,
5 isolates provided unique genotypes (2, 3, 6, 8 and 10), whereas
genotype 4 contained the highest number of isolates (n = 5).
The HLSR E. faecalis isolates were distributed in subgroups 1, 2
and 3.
4. Discussion
It has previously been documented that Enterococcus spp.
colonise the gastrointestinal tract of the vast majority of healthy
individuals [16]. Similarly, in the current study Enterococcus spp.
Table 7
Virulence gene profile of Enterococcus spp. isolated from healthy children in Iran.
Species Virulence genes Isolates [n (%)] No. of virulence genes Total [n (%)]a
E. faecium (N = 235) cylA, esp, asa1, hyl, gelE 1 (0.4) 5 1 (0.4)
cylA, esp, asa1, gelE 2 (0.8) 4 2 (0.8)
esp, asa1, gelE 9 (3.8) 3 16 (6.8)
asa1, hyl, gelE 4 (1.7) 3
cylA, esp, asa1 2 (0.9) 3
cylA, asa1, gelE 1 (0.4) 3
esp, gelE 11 (4.7) 2 51 (21.7)
asa1, gelE 33 (14.0) 2
asa1, hyl 2 (0.9) 2
hyl, gelE 1 (0.4) 2
esp, asa1 1 (0.4) 2
esp, hyl 3 (1.3) 2
gelE 45 (19.1) 1 69 (29.4)
asa1 18 (7.7) 1
esp 3 (1.3) 1
cylA 1 (0.4) 1
hyl 2 (0.9) 1
– 96 (41) 0 96 (40.9)
E. faecalis (N = 56) cylA, esp, asa1, gelE 1 (1.8) 4 1 (1.8)
cylA, esp, gelE 1 (1.8) 3 10 (17.8)
esp, asa1, gelE 8 (14.3) 3
cylA, esp, asa1 1 (1.8) 3
asa1, gelE 9 (16.1) 2 19 (34)
esp, gelE 5 (8.9) 2
cylA, asa1 4 (7.1) 2
esp, hyl 1 (1.8) 2
gelE 10 (17.9) 1 20 (35.7)
esp 1 (1.8) 1
hyl 2 (3.6) 1
asa1 7 (12.5) 1
– 6 (10.7) 0 6 (10.7)
a Total number of isolates harbouring the same number of virulence genes.
Table 8
Association of virulence genes with HLSR, HLGR and AR phenotypes in Enterococcus spp. isolated from healthy children in Iran.






















cylA 2 (5.0) 5 (2.6) 0.4 0 (0) 7 (3.0) 0.7 1 (14.3) 6 (2.6) 0.07 0 (0) 7 (13.7) 0.4
esp 6 (15.0) 26 (13.3) 0.8 1 (25.0) 31 (13.4) 0.5 0 (0) 32 (14.0) 0.3 1 (20.0) 17 (33.3) 0.5
asa1 15 (37.5) 57 (29.2) 0.3 2 (50.0) 70 (30.3) 0.4 2 (28.6) 70 (30.7) 0.9 1 (20.0) 28 (54.9) 0.1
hyl 3 (7.5) 11 (5.6) 0.6 1 (25.0) 13 (5.6) 0.1 1 (14.3) 13 (5.7) 0.3 1 (20.0) 3 (5.9) 0.2
gelE 24 (60.0) 83 (42.6) 0.04* 4 (100) 103 (44.6) 0.0* 4 (57.1) 103 (45.2) 0.5 2 (40.0) 31 (60.8) 0.4
HLSR, high-level streptomycin-resistant; HLGR, high-Level gentamicin-resistant; AR, ampicillin-resistant.
* Statistically significant (P  0.05).
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from healthy children. In this study, E. faecium (57.5% of isolates)
was the most prevalent coloniser of the gastrointestinal tract,
followed by other Enterococcus spp. (28.9%) and E. faecalis (13.7%).
These results are in agreement with the findings of Barreto et al.
[16] and Poeta et al. [17] which showed that E. faecium accounted
for >50% of enterococcal isolates recovered from healthy
volunteers. Regarding E. faecalis and other Enterococcus spp., the
current results are in contrast to those of the abovementioned
reports which showed that E. faecalis and other Enterococcus spp.
accounted for up to 40% and 10% of isolates [16,17]. In contrast to
stool samples from healthy people, E. faecalis is the most prevalent
species isolated from clinical specimens [18].
Despite the fact that there are plenty of studies reporting the
frequency of resistant enterococci in clinical specimens and faecal
samples from hospitalised patients, scarce data are available on the
distribution of resistant Enterococcus species in healthy human
faeces. Intestinal carriage of resistant enterococci is a significant
factor for the development of infection by the same organism and
is a potential source of dissemination of the organism in the
community [7,19].High-level gentamicin and streptomycin resistance were detected
in 11 (2.7%) and 71 (17.4%) of the 409 enterococcal isolates, respec-
tively. This finding is in contrast to a report by Kuzucu et al. on faecal
isolates of enterococci collected from outpatients in Turkey in which
10.0% and 3.0% of isolates were HLGR and HLSR, respectively [20]. In
the current study, HLGR and HLSR isolates mainly belonged to E.
faecium, being found in 4/11 (36.4%) and 40/71 (56.3%) of resistant
isolates, respectively. These results are in contrast to a report by
Asadian et al. in which no HLAR E. faecium was found in faecal
specimen from healthy volunteers [21]. However, in another study
much higher percentages of HLGR and HLSR enterococci were
reported in clinical isolates, with rates of 26.9% and 73.1% in E.
faecalis and 77.3% and 90.1% in E. faecium species, respectively [22].
Since resistance of enterococci to gentamicin and streptomycin
occurs by different mechanisms, streptomycin could be used as a
surrogate for gentamicin in the treatment of invasive enterococcal
infections. Co-existence of HLGR and HLSR limits the therapeutic
options of enterococcal infections. This phenomenonwas rare in the
current study. Co-existence of HLGR + HLSR, HLSR + AR and HLGR +
HLSR + AR resistance profiles was observed in one E. faecium isolate
each.
Fig. 1. Dendrogram of ERIC-PCR patterns showing the genetic relationship among
47 Enterococcus faecium isolates collected from healthy children in Ardabil, Iran.
Similarities >80% were considered for clustering of isolates. ERIC-PCR, entero-
bacterial repetitive intergenic consensus PCR; SG, subgroup.
Fig. 2. Dendrogram of ERIC-PCR patterns showing the genetic relationship among
19 Enterococcus faecalis isolates collected from healthy children in Ardabil, Iran.
Similarities >80% were considered for clustering of isolates. ERIC-PCR, entero-
bacterial repetitive intergenic consensus PCR; SG, subgroup.
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enterococcal isolates [23]. Low rates of ampicillin resistance were
observed in isolates obtained from healthy humans [21]. Accord-
ingly, in the current study a small numbers of isolates (10/409;2.4%) were found to be resistant to ampicillin. However, the current
results are higher than those from another study in which no AR
Enterococcus spp. were isolated from healthy people [17], but lower
than those from a study by Freitas et al. in which 50% of residents in
a long-term care facility in Portugal were colonised with AR
Enterococcus spp. [24]. The major reservoir of ampicillin resistance
was E. faecium (70.0%), followed by other Enterococcus spp. (30.0%).
No ampicillin resistance was observed in E. faecalis isolates. This is
in accordance with the fact that E. faecium is more resistant to
ampicillin and penicillin compared with E. faecalis [25]. Nowadays,
>90.0% of E. faecium isolates recovered from healthcare-associated
infections in the USA are resistant to ampicillin [23]. In another
study conducted in Ardabil, 19.0% and 28.0% of E. faecalis and E.
faecium isolates, respectively, obtained from clinical specimens in
2017 were resistant to ampicillin (authors’ unpublished data).
No vancomycin-resistant enterococci (VRE) were found in the
faeces of healthy subjects in this study. However, two E. faecium
isolates were intermediate-resistant to vancomycin. In contrast to
these results, intestinal colonisation with VRE in the healthy
population is frequently reported around the world. Rates of faecal
carriage of VRE in healthy people were recorded as 21.0%, 24.9% and
28.0% in Morocco, Taiwan and Belgium, respectively [26–28].
However, the result of the current study is in agreement with
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samples from healthy humans [21].
Regarding other routinely used antibiotics, erythromycin,
rifampicin and tetracycline were the most non-susceptible anti-
biotics both against E. faecalis and E. faecium isolates. Similar
results were reported for Enterococcus spp. isolated from faecal
specimens in Greek healthy infants [29]. Rifampicin resistance was
the highest, followed by resistance to tetracycline and erythromy-
cin [29]. Collectively, in this study majority of the HLAR and AR
enterococcal isolates obtained from healthy individuals were
resistant to multiple classes of antibiotics. Infections by MDR
organisms are serious global health problem causing significant
mortality [30,31].
Colonisation of healthy people with clinically important MDR
Enterococcus spp. could act as reservoir for the maintenance and
spread of resistant strains in the environment and hospital
settings. If factors promoting the acquisition of resistant organisms
are identified and controlled, it may be possible to control the
incidence of colonisation and thereby clinical infection. Previous
reports have indicated an association of colonisation or infection
with HLAR and AR enterococci with hospital stay and prior
antibiotic usage, especially use of broad-spectrum cephalosporins,
ampicillin and aminoglycosides [32–36]. Similarly, the current
results showed a positive association between HLAR and AR
enterococci intestinal carriage and prior antibiotic treatment.
However, in contrast to other studies [33,35], prior hospital stay
was not found to be a risk factor for HLAR or AR enterococcal
colonisation. Intestinal colonisation with HLSR enterococci was
positively associated the mean number of students in the
classroom. However, the heterogeneity of ERIC-PCR results among
HLAR isolates suggests no clonal dissemination for the spread of
these resistant enterococci. Similar to the current findings, a study
in Belgium by Schoevaerdts et al. reported antacid use as a risk
factor for methicillin-resistant Staphylococcus aureus (MRSA)
carriage [37].
In this study, all of the E. faecalis and E. faecium isolates were
examined for the presence of cylA, esp, asa1, hyl and gelE genes
encoding cytolysin activator, enterococcal surface protein, aggre-
gation substance, hyaluronidase and gelatinase, respectively. gelE
and asa1 were the most prevalent genes detected both in E. faecalis
and E. faecium. These results are in accordance with reports by
Shokoohizadeh et al. and Shahraki and Mousavi in which the gelE
and asa1 genes were the most prevalent virulence genes in E.
faecalis and E. faecium isolates collected from clinical specimens
[38,39]. However, some reports have indicated the absence or low
incidence of the gelE gene both in E. faecalis and E. faecium isolates
[40,41] and of the asa1 gene in E. faecium isolates [39,42]. In this
study, 50/56 (89.3%) and 139/235 (59.1%) E. faecalis and E. faecium
isolates possessed at least one virulence gene and 11 (19.6%) and 19
(8%) isolates contained at least three genes, respectively. This is in
contrast to previous studies reporting E. faecium isolates devoid of
multiple virulence factors [42–44]. The emergence of E. faecium
with multiple virulence factors along with its MDR characteristic
could lead to poor outcomes for enterococcal infection manage-
ment. Some previous reports showed a significant association
between the presence of virulence determinants and antimicrobial
resistance in Enterococcus spp. [45]. Accordingly, we also found a
significant correlation between the presence of gelE and HLAR
resistance in the isolates in the current study.
In summary, the results of this study show that a significant
proportion of Enterococcus spp. colonising a heathy population in
Iran was resistant to several classes of antibiotics. Moreover,
virulence-encoding genes were present in clinically important
species. Thus, healthy humans could act as a reservoir for
antimicrobial resistance and virulence genes, enabling the
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